In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...

Over the summer, we took a deep dive into “Ozempic Face,” a phenomenon that occurs when quick, significant weight loss leads ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Brands like Kourtney Kardashian’s Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...